Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL

Thomas Chatzikonstantinou, Mariia Mikhaleva, Christian Brieghel, Christina Papangelou, Evangelia Minga, Celso Arrais-Rodrigues, Sotiria Dimou-Besikli, Dr, Amalia Cerutti, Michael Doubek, Lisbeth Enggaard, Blanca Espinet, Blanca Ferrer-Lores, Jose Antonio Garcia Vela, Massimo Gentile, Eva Gimeno Vazquez, Odit Gutwein, Yair Herishanu, Paula Jabłonowska-Babij, Ozren Jaksic, Pär Josefsson, Elżbieta Kalicińska, Maria Kislova, Enrico Lista, Ioannis Kotsianidis, Juan Marquet, Enrica Antonia Antonia Martino, Ciaran P McAuley, Maria J Mela-Osorio, Riccardo Moia, Claudia Mosquera Rubal, Eugene A. Nikitin, Miguel Arturo Pavlovsky, Verena Pfister, Emine Merve Savaş, Lydia Scarfò, Matjaz Sever, Lev Shvidel, Martin Simkovic, Niki Stavroyianni, Persefoni Talimtzi, Antigoni Tranidou, Andrea Visentin, George Vrachiolias, Ewa Wasik-Szczepanek, Tomasz Wróbel, Münci Yağcı, Alessandro Cellini, Anastasia Chatzidimitriou, Gianluca Gaidano, Mary Ann Anderson, Matthew S. Davids, Jennifer R. Brown, Carsten Utoft Niemann, Kostas Stamatopoulos, Paolo Ghia, Inhye E. Ahn, Maya Koren-Michowitz

Blood Adv bloodadvances.2025017755.

https://doi.org/10.1182/bloodadvances.2025017755

Published: 2025

Includes: Supplemental data

Journal Articles

Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies

Blood Adv bloodadvances.2025015986.

https://doi.org/10.1182/bloodadvances.2025015986

Published: 2025

Includes: Supplemental data

Journal Articles

Statin use and survival in CLL/SLL treated with ibrutinib: pooled analysis of 4 randomized controlled trials

Ahmad Y. Abuhelwa, Sara A. Almansour, Jennifer R. Brown, Humaid O. Al-Shamsi, Ziad Abuhelwa, Zelal Kharaba, Yasser Bustanji, Mohammad H. Semreen, Salma Ali, Ahmad Alhuraiji, Ross A. McKinnon, Michael J. Sorich, Karem H. Alzoubi, Ashley M. Hopkins

Blood Adv (2025) 9 (14): 3566–3575.

https://doi.org/10.1182/bloodadvances.2024015287

Published: 2025

Includes: Supplemental data

Journal Articles

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis

Mazyar Shadman, Jennifer R. Brown, Leyla Mohseninejad, Keri Yang, Heather Burnett, Binod Neupane, Rhys Williams, Nicole Lamanna, Susan M. O'Brien, Alessandra Tedeschi, Constantine S. Tam

Blood Adv (2025) 9 (12): 2863–2870.

https://doi.org/10.1182/bloodadvances.2024014523

Published: 2025

Includes: Supplemental data

Journal Articles

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia

Blood Adv (2025) 9 (11): 2808–2817.

https://doi.org/10.1182/bloodadvances.2025016006

Published: 2025

Includes: Supplemental data

Journal Articles

Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study

Jennifer R. Brown, Jessica Li, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O’Brien, Constantine S. Tam, Lugui Qiu, Ruiqi Huang, Yang Shi, Adam Idoine, Tommi Salmi, Aileen Cleary Cohen, Mazyar Shadman

Blood Adv (2025) 9 (8): 1918–1926.

https://doi.org/10.1182/bloodadvances.2024014206

Published: 2025

Includes: Supplemental data

Journal Articles

Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL

Jacob D. Soumerai, Jacqueline Barrientos, Inhye Ahn, Catherine Coombs, Douglas Gladstone, Marc Hoffman, Adam Kittai, Ryan Jacobs, Andrew Lipsky, Krish Patel, Joanna Rhodes, Alan Skarbnik, Meghan Thompson, Daniel Ermann, Patrick Reville, Harsh Shah, Jennifer R. Brown, Deborah M. Stephens

Blood Adv (2025) 9 (5): 1213–1229.

https://doi.org/10.1182/bloodadvances.2024014474

Published: 2025

Includes: Supplemental data

Journal Articles

Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia

Abi Vijenthira, Virginia O. Volpe, Aswin Sekar, Roberta Santos Azevedo, Mariia Mikhaleva, Christopher J. Gibson, Stephen P. Martindale, Rayan Fardoun, Svitlana Tyekucheva, Yue Ren, Stacey M. Fernandes, Binyamin A. Knisbacher, Cynthia K. Hahn, Gad Getz, Catherine J. Wu, Matthew S. Davids, Jennifer R. Brown

Blood Adv (2024) 8 (23): 5949–5956.

https://doi.org/10.1182/bloodadvances.2024013414

Published: 2024

Includes: Supplemental data

Journal Articles

COVID-19 vaccination during therapy in relation to COVID-19 death in CLL

Jennifer R. Brown, Simon Rule, Kara Miller, John F. Seymour

Blood Adv (2024) 8 (20): 5262–5265.

https://doi.org/10.1182/bloodadvances.2024014121

Published: 2024

Journal Articles

Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib

Javid J. Moslehi, Richard R. Furman, Constantine S. Tam, Joe-Elie Salem, Christopher R. Flowers, Aileen Cohen, Meng Zhang, Jun Zhang, Lipeng Chen, Han Ma, Jennifer R. Brown

Blood Adv (2024) 8 (10): 2478–2490.

https://doi.org/10.1182/bloodadvances.2023011641

Published: 2024

Includes: Supplemental data

Journal Articles

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Blood Adv (2024) 8 (4): 832–841.

https://doi.org/10.1182/bloodadvances.2023011574

Published: 2024

Includes: Supplemental data

Journal Articles

Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation

Blood Adv (2023) 7 (17): 4748–4759.

https://doi.org/10.1182/bloodadvances.2022007706

Published: 2023

Includes: Supplemental data

Journal Articles

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

Blood Adv (2023) 7 (9): 1929–1943.

https://doi.org/10.1182/bloodadvances.2022008447

Published: 2023

Includes: Supplemental data

Journal Articles

Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies

Jennifer L. Crombie, Amy C. Sherman, Chi-An Cheng, Christine E. Ryan, Rebecca Zon, Michaël Desjardins, Peter Baker, Mikaela McDonough, Natalie Izaguirre, Bruce Bausk, Jonathan Krauss, Tal Gilboa, Yasmeen Senussi, David R. Walt, Matthew S. Davids, Jennifer R. Brown, Philippe Armand, Lindsey R. Baden, Nicolas Issa

Blood Adv (2021) 5 (16): 3062–3065.

https://doi.org/10.1182/bloodadvances.2021005328

Published: 2021

Journal Articles

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia

Haesook T. Kim, Conner J. Shaughnessy, Sharmila C. Rai, Carol Reynolds, Vincent T. Ho, Corey Cutler, John Koreth, Mahasweta Gooptu, Rizwan Romee, Sarah Nikiforow, Philippe Armand, Edwin P. Alyea, Joseph H. Antin, Catherine J. Wu, Robert J. Soiffer, Jerome Ritz, Jennifer R. Brown

Blood Adv (2020) 4 (17): 4113–4123.

https://doi.org/10.1182/bloodadvances.2020002184

Published: 2020

Includes: Supplemental data

Journal Articles

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Blood Adv (2020) 4 (16): 3977–3989.

https://doi.org/10.1182/bloodadvances.2020001956

Published: 2020

Journal Articles

Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors

Christine E. Ryan, Matthew P. Cheng, Nicolas C. Issa, Jennifer R. Brown, Matthew S. Davids

Blood Adv (2020) 4 (7): 1458–1463.

https://doi.org/10.1182/bloodadvances.2020001678

Published: 2020

Journal Articles

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma

Blood Adv (2020) 4 (5): 858–867.

https://doi.org/10.1182/bloodadvances.2019001355

Published: 2020

Includes: Supplemental data

Journal Articles

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

Farrukh T. Awan, Anna Schuh, Jennifer R. Brown, Richard R. Furman, John M. Pagel, Peter Hillmen, Deborah M. Stephens, Jennifer Woyach, Elena Bibikova, Prista Charuworn, Melanie M. Frigault, Ahmed Hamdy, Raquel Izumi, Bolan Linghu, Priti Patel, Min Hui Wang, John C. Byrd

Blood Adv (2019) 3 (9): 1553–1562.

https://doi.org/10.1182/bloodadvances.2018030007

Published: 2019

Journal Articles

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia

Benjamin L. Lampson, Haesook T. Kim, Matthew S. Davids, Jeremy S. Abramson, Arnold S. Freedman, Caron A. Jacobson, Philippe A. Armand, Robin M. Joyce, Jon E. Arnason, Laura Z. Rassenti, Thomas J. Kipps, Joshua Fein, Stacey M. Fernandes, John R. Hanna, David C. Fisher, Jennifer R. Brown

Blood Adv (2019) 3 (7): 1167–1174.

https://doi.org/10.1182/bloodadvances.2018030221

Published: 2019

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL

Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies

Statin use and survival in CLL/SLL treated with ibrutinib: pooled analysis of 4 randomized controlled trials

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia

Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study

Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL

Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia

COVID-19 vaccination during therapy in relation to COVID-19 death in CLL

Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only